Evaluating Tirzepatide with Lifestyle Modification in Overweight Adults with Type 2 Diabetes: A Real-World Clinical Study

Dr. Chhavi Mehra, Madan Somasundaram, Ashish Goyal, Chandra Mukherjee, Ankitha Sequeira, Jeny Joseline J, Shivtosh Kumar

Abstract: This real-world clinical study assessed the effectiveness of tirzepatide, a dual GIP/GLP-1 receptor agonist, in combination with structured lifestyle modification among adults with type 2 diabetes and overweight or obesity. Conducted through a virtually assisted diabetes care platform, the 8-week intervention enrolled 41 participants who received tirzepatide starting at 2.5 mg, with some escalating to 5 mg based on response. Of the participants, 31 continued treatment and completed an 8-week follow-up, exhibiting significant weight reduction (4.56 ± 2.97; p <0.001). Subgroup analysis revealed significantly greater weight loss in the 5 mg dose-escalation group compared to the 2.5 mg group (5.22 ± 3.63 kg vs. 3.84 ± 1.94 kg; p<0.001). Significant reductions were also observed in BMI, waist circumference, and blood glucose levels, with dose-dependent trends evident. Adverse events were predominantly mild and transient, primarily gastrointestinal in nature. The combined pharmacologic and lifestyle approach demonstrated promising efficacy and safety in short-term diabetes management, highlighting tirzepatide's potential role in real-world integrated care models.

Keywords: Tirzepatide, Type 2 Diabetes, Lifestyle Intervention, Overweight, Glycemic Control

How to Cite?: Dr. Chhavi Mehra, Madan Somasundaram, Ashish Goyal, Chandra Mukherjee, Ankitha Sequeira, Jeny Joseline J, Shivtosh Kumar, "Evaluating Tirzepatide with Lifestyle Modification in Overweight Adults with Type 2 Diabetes: A Real-World Clinical Study", Volume 14 Issue 9, September 2025, International Journal of Science and Research (IJSR), Pages: 1141-1157, https://www.ijsr.net/getabstract.php?paperid=SR25919183931, DOI: https://dx.doi.org/10.21275/SR25919183931